Clinical Significance of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide in Pediatric Patients: Insights into Their Utility in the Presence or Absence of Pre-Existing Heart Conditions
- PMID: 39201467
- PMCID: PMC11354905
- DOI: 10.3390/ijms25168781
Clinical Significance of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide in Pediatric Patients: Insights into Their Utility in the Presence or Absence of Pre-Existing Heart Conditions
Abstract
The clinical significance of B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in pediatric patients remains an area of evolving understanding, particularly regarding their utility in the presence or absence of pre-existing heart conditions. While clear cutoff values and established roles in heart failure are understood in adult patients, pediatric norms vary with age, complicating interpretation. Notably, the emergence of multi-system inflammatory syndrome in children (MIS-C) has highlighted the importance of these markers not only in the detection of acute heart failure but also as a marker of disease severity and even as a differential diagnosis tool. This review summarizes current knowledge on the utility of BNP and NT-proBNP in pediatric patients. Their unique physiology, including circulation and compensation mechanisms, likely influence BNP and NT-proBNP release, potentially even in non-heart failure states. Factors such as dynamic volemic changes accompanying inflammatory diseases in children may contribute. Thus, understanding the nuanced roles of BNP and NT-proBNP in pediatric populations is crucial for the accurate diagnosis, management, and differentiation of cardiac and non-cardiac conditions.
Keywords: BNP; Kawasaki disease; MIS-C; children; heart failure.
Conflict of interest statement
K.M.L., B.P., and L.S. are employees of Wroclaw Medical University. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures
Similar articles
-
The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.Intern Med. 2018 Sep 15;57(18):2621-2630. doi: 10.2169/internalmedicine.0471-17. Epub 2018 Apr 27. Intern Med. 2018. PMID: 29709934 Free PMC article.
-
B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function.BMC Nephrol. 2013 May 31;14:117. doi: 10.1186/1471-2369-14-117. BMC Nephrol. 2013. PMID: 23725445 Free PMC article.
-
The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update.Heart Fail Rev. 2014 Nov;19(6):727-42. doi: 10.1007/s10741-014-9422-2. Heart Fail Rev. 2014. PMID: 24473828 Review.
-
Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.Clin Chim Acta. 2019 Apr;491:8-14. doi: 10.1016/j.cca.2018.12.025. Epub 2018 Dec 28. Clin Chim Acta. 2019. PMID: 30594544
-
Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment.Ont Health Technol Assess Ser. 2021 May 6;21(2):1-125. eCollection 2021. Ont Health Technol Assess Ser. 2021. PMID: 34055110 Free PMC article.
Cited by
-
Cardiac Markers in Pediatric Laboratory Medicine: Critical Review.Diagnostics (Basel). 2025 Jan 13;15(2):165. doi: 10.3390/diagnostics15020165. Diagnostics (Basel). 2025. PMID: 39857049 Free PMC article. Review.
-
Longitudinal Myocardial Deformation as an Emerging Biomarker for Post-Traumatic Cardiac Dysfunction.Life (Basel). 2025 Jun 30;15(7):1052. doi: 10.3390/life15071052. Life (Basel). 2025. PMID: 40724554 Free PMC article. Review.
-
Diagnostic Efficacy of Combined N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Cardiac Troponin I (cTnI) Testing in Myocardial Injury of Children with Mycoplasma Pneumoniae Pneumonia.J Multidiscip Healthc. 2025 Jun 26;18:3709-3716. doi: 10.2147/JMDH.S527700. eCollection 2025. J Multidiscip Healthc. 2025. PMID: 40600200 Free PMC article.
-
Contemporary Diagnosis, Management, and Early Outcomes in Children with Kawasaki Disease in Romania: A Single-Center Experience.Diagnostics (Basel). 2025 Mar 7;15(6):656. doi: 10.3390/diagnostics15060656. Diagnostics (Basel). 2025. PMID: 40149999 Free PMC article.
References
-
- Mueller C., McDonald K., de Boer R.A., Maisel A., Cleland J.G.F., Kozhuharov N., Coats A.J.S., Metra M., Mebazaa A., Ruschitzka F., et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur. J. Heart Fail. 2019;21:715–731. doi: 10.1002/ejhf.1494. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials